Vectura and Inspira Pharmaceuticals sign Agreement on Development of Potential Inhaled Treatment for COVID-19

Chippenham, UK and London, UK – 6 May 2021: Vectura Group plc, an industry leading inhalation CDMO, and Inspira Pharmaceuticals Limited, a new UK-based company focused on developing therapies for respiratory and infectious diseases, today announced an agreement to develop an inhaled formulation of Inspira’s lead drug candidate for the treatment of COVID-19.

Read full release here